DMAA · Drugs Made in America Acquisition Corp. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - |
| SG&A | $143.3K | - | $263.7K | $131.9K | $330.9K | - |
| Total Operating Expenses | $94.6K | - | - | - | - | - |
| D&A | - | - | - | - | - | - |
| Operating Income | ($143.3K) | - | ($263.7K) | ($131.9K) | ($330.9K) | - |
| Interest Expense | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - |
| Net Income | $1.97M | - | $2.18M | $2.29M | $1.25M | - |
| EPS - Basic | - | - | - | - | - | - |
| EPS - Diluted | - | - | - | - | - | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $14.9K | $6.1K | $2.1K | $822 | $923 | $1.4K |
| Accounts Receivable | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | - | - | - | - | - | - |
| Current Assets | $14.9K | $12.2K | $28.2K | $49.7K | $71.0K | $5.0K |
| Total Assets | $242.04M | $239.92M | $237.63M | $235.21M | $232.81M | $550.8K |
| Current Liabilities | $492.2K | $376.2K | $456.6K | $301.4K | $347.4K | - |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $7.39M | $7.28M | $7.36M | $7.20M | $7.25M | $795.7K |
| Stockholders' Equity | ($7.38M) | ($7.26M) | ($164.9K) | ($7.15M) | ($7.18M) | ($244.8K) |
| Retained Earnings | ($7.38M) | ($7.27M) | ($6.72M) | ($6.46M) | ($6.33M) | ($279.8K) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($91.3K) | - | - | - | ($251.2K) | - |
| Investing Cash Flow | - | - | - | - | ($231.15M) | - |
| Financing Cash Flow | $100.0K | - | - | - | $231.40M | - |
| CapEx | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | 0.8% | - | 0.9% | 1.0% | 0.5% | - |
| Return on equity | -26.7% | - | -1325.1% | -32.0% | -17.5% | - |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 0.03 | 0.03 | 0.06 | 0.16 | 0.20 | - |
| Quick ratio | 0.03 | 0.03 | 0.06 | 0.16 | 0.20 | - |
| Cash ratio | 0.03 | 0.02 | 0.00 | 0.00 | 0.00 | - |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - |
| Equity multiplier | -32.81 | -33.03 | -1441.43 | -32.89 | -32.44 | -2.25 |
| Liabilities / Assets | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 1.44 |
| Efficiency | ||||||
| Asset turnover | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | 56.7% | - | - | - | - | - |
| Net income growth (YoY) | 57.1% | - | - | - | - | - |
| EPS growth (YoY) | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -2.8% | -2866.8% | - | - | - | - |
Peer comparison
Same SIC group: Blank Checks
Comparing Drugs Made In America Acquisition Corp. against the 5 most active filers in the same SIC group.